PARIS — Early use of an implantable cardioverter defibrillator after primary PCI lengthened survival among high-risk patients with STEMI, according to results of the DAPA trial reported at the European Society of Cardiology Congress.
Would you like to receive email reminders to complete your saved activities from Healio CME?
Activity saved! You'll receive reminders to complete your saved activities from Healio CME.